PrithvirajBoseMD

PubMed

• Exploring the landscape of somatic ASXL2 mutations in myeloid neoplasms: Frequency and clinical implications.
  Tareq Abuasab, Gautam Borthakur, Rashmi Kanagal-Shamanna, Lucia Masarova, Keyur Patel, Koichi Takahashi, Prithviraj Bose, John Villarreal, Sherry Pierce, Tapan Kadia, ...> ;American Journal of Hematology. 2024 Apr 13
• Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study.
  Prithviraj Bose, Lucia Masarova, Naveen Pemmaraju, Sharon D Bledsoe, Naval G Daver, Elias J Jabbour, Tapan M Kadia, Zeev Estrov, Steven M Kornblau, Michael Andreeff, N...> ;Haematologica. 2024 Apr 4
• 1 citations
  Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm,...
  Alexandre Bazinet, Hagop Kantarjian, Alex Bataller, Naveen Pemmaraju, Gautam Borthakur, Kelly Chien, Yesid Alvarado, Prithviraj Bose, Elias Jabbour, Musa Yilmaz, Court...> ;The Lancet. Haematology. 2024 Apr 1
• Management of Patients with Early Myelofibrosis: A Discussion of Best Practices.
  Prithviraj Bose> ;Current Hematologic Malignancy Reports. 2024 Mar 5
• Multicolor flow cytometric immunophenotyping is highly sensitive and specific in identifying aberrant mast cells in the diagnostic workup of systemic mastocytosis.
  Medeiros, L., Nwogbo, O., Fang, H., Wang, W., Xu, J., Miranda, R., Bose, P., Ok, C., Jorgensen, J., Wang, S.> ;American Journal of Clinical Pathology. 2024 Feb 19
• A randomized, double-blind study of zinpentraxin alfa in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: Stage 2 of a phase...
  Verstovsek, S., Talpaz, M., Wadleigh, M., Isidori, A., Te Boekhorst, P., Savona, M., Bose, P., Pozdnyakova, O., Mesa, R., El-Galaly, T., O'Sullivan, J., Gamel, K., Hig...> ;Haematologica. 2024 Jan 25
• SOHO State of the Art Updates and Next Questions | Diagnosis, Outcomes, and Management of Prefibrotic Myelofibrosis.
  Vachhani, P., Loghavi, S., Bose, P.> ;Clinical Lymphoma, Myeloma & Leukemia. 2024 Jan 21
• Interferons in the treatment of myeloproliferative neoplasms.
  Pankit Vachhani, John Mascarenhas, Prithviraj Bose, Gabriela Hobbs, Abdulraheem Yacoub, Jeanne M Palmer, Aaron T Gerds, Lucia Masarova, Andrew T Kuykendall, Raajit K R...> ;Therapeutic Advances in Hematology. 2024 Jan 1
• 2 citations
  Moving toward disease modification in polycythemia vera.
  Jan Philipp Bewersdorf, Joan How, Lucia Masarova, Prithviraj Bose, Naveen Pemmaraju, John Mascarenhas, Raajit K Rampal> ;Blood. 2023 Nov 30
• Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia.
  Tapan M Kadia, Farhad Ravandi, Matteo Molica, Alex Bataller, Gautam Borthakur, Naval Daver, Elias Jabbour, Courtney D DiNardo, Naveen Pemmaraju, Nitin Jain, Alessandra...> ;American Journal of Hematology. 2023 Nov 1
• 24 citations
  Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis.
  Stephen T Oh, Ruben A Mesa, Claire N Harrison, Prithviraj Bose, Aaron T Gerds, Vikas Gupta, Bart L Scott, Jean-Jacques Kiladjian, Alessandro Lucchesi, Tim Kong, Sarah ...> ;Blood Advances. 2023 Oct 10
• 8 citations
  A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents.
  Nicholas J Short, Muharrem Muftuoglu, Faustine Ong, Lewis Nasr, Walid Macaron, Guillermo Montalban-Bravo, Yesid Alvarado, Mahesh Basyal, Naval Daver, Courtney D Dinard...> ;Journal of Hematology & Oncology. 2023 Jul 8
• 3 citations
  Association of Myelofibrosis Phenotypes with Clinical Manifestations, Molecular Profiles, and Treatments.
  Helen T Chifotides, Srdan Verstovsek, Prithviraj Bose> ;Cancers. 2023 Jun 24
• 6 citations
  Avapritinib versus Placebo in Indolent Systemic Mastocytosis.
  Gotlib, J., Castells, M., Elberink, H., Siebenhaar, F., Hartmann, K., Broesby-Olsen, S., George, T., Panse, J., Alvarez-Twose, I., Radia, D., Tashi, T., Bulai Lividean...> ;NEJM Evidence. 2023 Jun 1
• 1 citations
  The role of therapy in the outcome of patients with myelofibrosis.
  Lucia Masarova, Prithviraj Bose, Naveen Pemmaraju, Naval G Daver, Koji Sasaki, Helen T Chifotides, Lingsha Zhou, Hagop M Kantarjian, Zeev Estrov, Srdan Verstovsek> ;Cancer. 2023 Sep 15
• An update on the efficacy of Venetoclax for chronic lymphocytic leukemia.
  Alexandra R Lovell, Jacki Sawyers, Prithviraj Bose> ;Expert Opinion on Pharmacotherapy. 2023 May 29
• 1 citations
  Moving beyond ruxolitinib failure in myelofibrosis: evolving strategies for second line therapy.
  Prithviraj Bose, Andrew T Kuykendall, Carole Miller, Sandra Kurtin, Kyle Farina, Donald M Harting, John O Mascarenhas, Ruben A Mesa> ;Expert Opinion on Pharmacotherapy. 2023 Jun 1
• 2 citations
  Venetoclax consolidation in high-risk CLL treated with ibrutinib for ≥1 year achieves a high rate of undetectable MRD.
  Philip A Thompson, Michael J Keating, Alessandra Ferrajoli, Nitin Jain, Christine B Peterson, Naveen Garg, Sa A Wang, Jeffrey L Jorgensen, Tapan M Kadia, Prithviraj Bo...> ;Leukemia. 2023 Jul 1
• 35 citations
  A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies.
  Curtis A Lachowiez, Sanam Loghavi, Zhihong Zeng, Tomoyuki Tanaka, Yi June Kim, Hidetaka Uryu, Sven Turkalj, Niels Asger Jakobsen, Marlise R Luskin, Dzifa Y Duose, Rebe...> ;Blood Cancer Discovery. 2023 Jul 5
• 6 citations
  Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy.
  Naveen Pemmaraju, Prithviraj Bose, Raajit Rampal, Aaron T Gerds, Angela Fleischman, Srdan Verstovsek> ;Leukemia & Lymphoma. 2023 Jun 1
• 2 citations
  Cytopenic myelofibrosis: prevalence, relevance, and treatment.
  Pankit Vachhani, Srdan Verstovsek, Prithviraj Bose> ;Expert Opinion on Pharmacotherapy. 2023 Jun 1
• 68 citations
  Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials.
  Timothy A Yap, Naval Daver, Mikhila Mahendra, Jixiang Zhang, Carlos Kamiya-Matsuoka, Funda Meric-Bernstam, Hagop M Kantarjian, Farhad Ravandi, Meghan E Collins, Maria ...> ;Nature Medicine. 2023 Jan 1
• 1 citations
  Relevant Clinical Factors in Patients with Myelofibrosis on Ruxolitinib for 5 or More Years.
  Lingsha Zhou, Sherry Pierce, Masarova, L., Bose, P., Pemmaraju, N., Estrov, Z., Kantarjian, H., Verstovsek, S.> ;Acta Haematologica. 2023 Jan 1
• EXABS-161-MPN Management of Pre-Fibrotic Primary Myelofibrosis.
  Prithviraj Bose> ;Clinical Lymphoma, Myeloma & Leukemia. 2022 Oct 1
• 2 citations
  Treating Anemic Patients With Myelofibrosis in the New Janus Kinase Inhibitor Era: Current Evidence and Real-world Implications.
  Aaron T Gerds, Prithviraj Bose, Gabriela S Hobbs, Andrew T Kuykendall, Lynn M Neilson, Jinlin Song, Barbara Klencke, Claire N Harrison> ;Hemasphere. 2022 Oct 1
• Join now to see all

Journal Articles

• Mutational Landscape of myelodysplastic/myeloproliferative Neoplasm – Unclassifiable (MDS/MPN-U)  
  Aziz Nazha, Rami S Komrokji, Andrew Sochacki, Mikkael A Sekeres, Prithviraj Bose, Courtney D DiNardo, Hagop M Kantarjian, Srdan Verstovsek, Sanam Loghavi, Jaroslaw P M..., Blood
• Final Results of a Randomized Multicenter Phase II Study of Alvocidib, Cytarabine, and Mitoxantrone Versus Cytarabine and Daunorubicin (7+3) in Newly Diagnosed High-Ri...  
  Joshua F Zeidner, Mark R Litzow, Jeffrey E Lancet, Prithviraj Bose, Raoul Tibes, Ivana Gojo, Richard F Little, Judith E Karp, Leukemia Research
• Cyclin dependent kinase inhibitor therapy for hematologic malignancies  
  Bose P, Simmons GL, Grant S, Expert Opin Investig Drugs, 5/6/2013
• It’s not always ITP: a case of MYH9-related platelet disorder caused by a novel mutation  
  Skiver BM, Patel SB, Bose P, Eur J Haematol, 3/12/2013
• Mcl-1 as a Therapeutic Target in Acute Myelogenous Leukemia (AML)  
  Bose P, Grant S, Leukemia Research Reports, 1/1/2013
• Strategies to circumvent the T315I gatekeeper mutation in the BCR-ABL tyrosine kinase  
  Bose P, Park H, Al-Khafaji J, Grant S, Leukemia Research Reports, 1/1/2013
• Coordinate PI3K pathway and Bcl-2 family disruption in AML  
  Bose P, Rahmani M, Grant S, Oncotarget, 12/1/2012
• Complementary combinations: What treatments will become key to the battle against AML?  
  Bose P, Grant S, Expert Rev Hematol, 10/1/2012
• Extraosseous Ewing’s sarcoma of the pancreas  
  Bose P, Murugan P, Gillies E, Holter JL, 8/1/2012
• Phase I Trial of the Combination of Flavopiridol and Imatinib Mesylate in Patients with Bcr-Abl+ Hematological Malignancies  
  Bose P, Perkins EB, Honeycut C, Wellons MD, Stefan T, Jacobberger JW, Kontopodis E, Beumer JH, Egorin MJ, Imamura CK, Figg WD, Karp JE, Koc ON, Cooper B, Luger SM, Col..., Cancer Chemother Pharmacol, 6/1/2012
• A review of tumor lysis syndrome with targeted therapies and the role of rasburicase  
  Bose P, Qubaiah O, J Clin Pharm Ther, 6/1/2011
• Disseminated fusariosis occurring in two patients despite posaconazole prophylaxis  
  Bose P, Parekh, Holter JL, Greenfield RA, J Clin Microbiol, 4/1/2011
• C-Kit Expression and Mutations in Phyllodes Tumors of the Breast  
  Bose P, Dunn ST, Yang JT, Allen RA, El-Khoury C, Tfayli A, Anticancer Res, 1/1/2010
• Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer  
  Bose P, Ozer H, Expert Opin Investig Drugs, 11/1/2009
• More on Bevacizumab in Hereditary Hemorrhagic Telangiectasia (author reply)  
  Bose P, Holter JL, Selby GB, N Engl J Med, 8/27/2009
• Successful treatment of cyclic thrombocytopenia with thrombopoietic agents: a report of two patients  
  Bose P, Hussein KK, Terrell DR, Berger D, Rice L, George JN, Am J Hematol, 7/1/2009
• AIDS-related plasmablastic lymphoma with dramatic, early response to bortezomib  
  Bose P, Thompson C, Gandhi D, Ghabach B, Ozer H, Eur J Haematol, 6/1/2009
• Bevacizumab in Hereditary Hemorrhagic Telangiectasia  
  Bose P, Holter JL, Selby GB, N Engl J Med, 5/1/2009
• Join now to see all

Books/Book Chapters

• Gastrointestinal Stromal Tumor 
  Chapter: Molecularly Targeted Therapy: Imatinib and Beyond 
  Page 47 - 60Poklepovic A, Bose PEditors: Raimundas Lunevicius.©InTech, Croatia2012
• Pancreas: Anatomy, Diseases and Health Implications 
  Chapter: Emerging therapeutic options for metastatic exocrine pancreatic cancer 
  Page 159 - 172Park H, Poklepovic A, Bose PEditors: Akiko Satou and Hana Nakamura.©Nova Science Publishers Inc., New York2012

Abstracts/Posters

• Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)
  Prithviraj Bose, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Constitutively Activated STAT3 Induces the Production of PTX3 That Contributes to the Induction of Bone Marrow Reticulin Fibrosis in Patient with CLL
  Prithviraj Bose, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Final Results of Phase 2 Clinical Trial of LCL161, a Novel Oral SMAC Mimetic/IAP Antagonist, for Patients with Intermediate to High Risk Myelofibrosis
  Prithviraj Bose, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)
  Prithviraj Bose, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Pre-Clinical Efficacy of Co-Treatment with KDM1A (LSD1) Inhibitor and Ruxolitinib or BET Inhibitor Against Post-MPN-sAML Blast Progenitor Cells
  Prithviraj Bose, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Venetoclax Added to Ibrutinib in High-Risk CLL Achieves a High Rate of Undetectable Minimal Residual Disease. [RTS1]
  Prithviraj Bose, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Phase II Trial of Azacitidine (AZA) in Combination with Ruxolitinib (RUX) in Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPNs)
  Prithviraj Bose, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV-Mutated CLL and without Del(17p)/Mutated TP53
  Prithviraj Bose, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens
  Prithviraj Bose, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Constitutively Activated STAT3 Induces the Expression of Gli1 in Chronic Lymphocytic Leukemia Cells
  Prithviraj Bose, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• The Early Achievement of Measurable Residual Disease Negativity in the Treatment of Adults with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia Is a Strong P...
  Prithviraj Bose, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: A Phase II Study
  Prithviraj Bose, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Effectiveness of Bosutinib in Chronic Myeloid Leukemia (CML) Who Have Received Multi Tyrosine Kinase Inhibitors (TKIs)
  Prithviraj Bose, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia
  Prithviraj Bose, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Characteristics and Outcomes of Therapy-Related Versus De Novo Acute Myeloid Leukemia with Normal Karyotype
  Prithviraj Bose, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II TrialClinically Relevant Abstract
  Prithviraj Bose, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Updated Preliminary Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome
  Prithviraj Bose, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Phase 2 Study of Ruxolitinib (RUX) in Combination with 5-Azacitidine (AZA) in Patients (pts) with Myelofibrosis
  Prithviraj Bose, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), As Monotherapy or Add-on to Ruxolitinib, in Patients with Refractory or...
  Prithviraj Bose, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Phase I Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, or Peripheral T-Cell Lym...
  Beata Holkova, Thomas C. Shea, Prithviraj Bose, Mary Beth Tombes, Ellen Shrader, Wen Wan, Caryn Weir-Wiggins, Elizabeth Stoddert, Heidi Sankala, Maciej Kmieciak, John ..., 54th American Society of Hematology annual meeting, Atlanta, GA, 12/1/2012
• Phase I Trial of Belinostat and Bortezomib in Patients with Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia in Blast C...
  Beata Holkova, Prithviraj Bose, Mary Beth Tombes, Ellen Shrader, Wen Wan, Caryn Weir-Wiggins, Elizabeth Stoddert, Heidi Sankala, Maciej Kmieciak, John D. Roberts, Guil..., 54th American Society of Hematology annual meeting, Atlanta, GA, 12/1/2012
• Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms – Update o...
  Beata Holkova, E. Brent Perkins, Prithviraj Bose, Daniel Sullivan, Rachid C. Baz, Mary Beth Tombes, Ellen Shrader, Viswanathan Ramakrishnan, Wen Wan, Heidi Sankala, Ma..., 54th American Society of Hematology annual meeting, Atlanta, GA, 12/1/2012
• Randomized Phase II Trial of Timed-Sequential Therapy (TST) with Flavopiridol (Alvocidib), Ara-C and Mitoxantrone (FLAM) Versus "7+3" for Adults Ages 70 Years and Unde...
  Joshua F. Zeidner, Jonathan M. Gerber, Amanda Blackford, Mark Litzow, Matthew Foster, Lawrence Morris, Ivana Gojo, Jeffrey Lancet, Prithviraj Bose, Raoul Tibes, Stephe..., Blood, 11/1/2012
• Phase I Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, or Peripheral T-Cell Lym...
  Beata Holkova, Thomas C. Shea, Prithviraj Bose, Mary Beth Tombes, Ellen Shrader, Wen Wan, Caryn Weir-Wiggins, Elizabeth Stoddert, Heidi Sankala, Maciej Kmieciak, John ..., Blood, 11/1/2012
• Phase I Trial of Belinostat and Bortezomib in Patients with Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia in Blast C...
  Beata Holkova, Prithviraj Bose, Mary Beth Tombes, Ellen Shrader, Wen Wan, Caryn Weir-Wiggins, Elizabeth Stoddert, Heidi Sankala, Maciej Kmieciak, John D. Roberts, Guil..., Blood, 11/1/2012
• Join now to see all

Lectures

• Present Strategies and Future Directions: Treating MDS and MPN 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Final Report of a Phase II Study of Guadecitabine (SGI-110) in Patients (pts) with Previously Untreated Myelodysplastic Syndrome (MDS) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Five-Day Versus Ten-Day Schedules of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase II Study 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Evaluation of Cytogenetic Stratifications in Myelofibrosis 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Novel BET Protein Degrader-Based Combinations Exert Lethality Against Human AML Resistant to BET Inhibitors Due to Increased Activity of β-Catenin-TCF7L2- MYC Axis 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk Chronic Lymphocytic Leukemia (CLL) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Chronic Lymphocytic Leukemia 
  Hematology/Oncology fellows’core lecture series. Virginia Commonwealth University, Richmond, VA - 6/25/2013
• Targeted therapies and rational combinations for the myeloid malignancies 
  VCU Massey Cancer Center Clinical Research Affiliations Network Second Annual Retreat. Hilton Garden - 6/7/2013
• Chronic Myeloid Leukemia 
  Hematology/Oncology fellows’core lecture series. Virginia Commonwealth University, Richmond, VA - 4/23/2013
• Concomitant HDAC and Wee1 inhibition in AML 
  6th Annual SEPIIC meeting, Sheraton Sand Key Resort, Clearwater Beach, FL - 1/12/2013
• Randomized Phase II Trial of Timed-Sequential Therapy (TST) with Flavopiridol (Alvocidib), Ara-C and Mitoxantrone (FLAM) Versus "7+3" for Adults Ages 70 Years and Unde... 
  54th annual meeting of the American Society of Hematology, Atlanta, GA - 12/1/2012
• ASH CRTI Final Class Presentation 
  American Society of Hematology Headquarters, Washington, DC - 5/17/2012
• Clinicopathologic Conference (CME-accredited) 
  Internal Medicine Grand Rounds. Virginia Commonwealth University, Richmond, VA - 11/3/2011
• Phase I Trial of Sorafenib and Obatoclax in Relapsed or Refractory AML or MDS 
  American Society of Hematology Clinical Research Training Institute, Estancia La Jolla, La Jolla, CA - 8/5/2011
• Tumor Lysis Syndrome 
  Hematology/Oncology fellows’core lecture series. Virginia Commonwealth University, Richmond, VA, 201 - 7/26/2011
• Chronic Leukemias 
  Internal Medicine Residents’ core lecture series. Virginia Commonwealth University, Richmond, VA - 4/12/2011
• What’s New In ITP (CME-accredited) 
  Hematology, Oncology and Palliative Care Grand Rounds. Virginia Commonwealth University, Richmond, V - 2/1/2011
• Chronic Myelogenous Leukemia 
  Hematology-Oncology Grand Rounds. University of Oklahoma Health Sciences Center, Oklahoma City, OK - 10/9/2009
• Best Consult Case of the Month (Heparin-induced thrombocytopenia, CME-accredited) 
  University of Oklahoma Health Sciences Center, Oklahoma City, OK - 3/27/2009
• Chronic Lymphocytic Leukemia (CME-accredited) 
  Hematology-Oncology Grand Rounds. University of Oklahoma Health Sciences Center, Oklahoma City, OK - 1/9/2009
• Ductal Carcinoma In Situ 
  Breast Multidisciplinary Conference. University of Oklahoma Health Sciences Center, Oklahoma City, O - 9/10/2008
• Best consult case of the month (Plasmablastic lymphoma, CME-accredited) 
  Hematology-Oncology Grand Rounds. University of Oklahoma Health Sciences Center, Oklahoma City, OK - 8/29/2008
• Renal cell carcinoma (CME-accredited) 
  Hematology-Oncology Grand Rounds. University of Oklahoma Health Sciences Center, Oklahoma City, OK - 5/2/2008
• Join now to see all